Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous cell carcinoma (HNSCC) but benefits a minority. An established tumor-intrinsic resistance mechanism is cross-talk between the EGFR and hepatocyte growth factor (HGF)/cMet pathways. Dual pathway inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauman, Julie E., Ohr, James, Gooding, William E., Ferris, Robert L., Duvvuri, Umamaheswar, Kim, Seungwon, Johnson, Jonas T., Soloff, Adam C., Wallweber, Gerald, Winslow, John, Gaither-Davis, Autumn, Grandis, Jennifer R., Stabile, Laura P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352434/
https://www.ncbi.nlm.nih.gov/pubmed/32545260
http://dx.doi.org/10.3390/cancers12061537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352434/
https://www.ncbi.nlm.nih.gov/pubmed/32545260
http://dx.doi.org/10.3390/cancers12061537

Ejemplares similares